文献速递胸部肿瘤

Bintrafusp Alfa联合同步放化疗后Bintrafusp Alfa对比安慰剂联合同步放化疗后度伐利尤单抗治疗不可切除III期非小细胞肺癌:一项2期随机研究

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.
PubMed 文献 · J Thorac Oncol · 2023-10-04

这项多中心、双盲、对照2期研究纳入153例不可切除III期非小细胞肺癌患者,随机分为BA联合cCRT后BA组(n=75)或安慰剂联合cCRT后度伐利尤单抗组(n=78)。BA组与度伐利尤单抗组中位无进展生存期分别为12.8个月与14.6个月(分层风险比=1.48,95%CI:0.69-3.17),客观缓解率分别为29.3%与32.1%,疾病控制率分别为66.7%与70.5%。结论:BA联合cCRT后BA相比安慰剂联合cCRT后度伐利尤单抗未显示出疗效获益。

要点

  • BA组与度伐利尤单抗组中位PFS分别为12.8个月与14.6个月,分层HR=1.48(95%CI:0.69-3.17)。
  • BA组与度伐利尤单抗组客观缓解率分别为29.3%与32.1%,疾病控制率分别为66.7%与70.5%。
  • BA组与度伐利尤单抗组任何级别治疗中出现的不良事件发生率分别为94.6%与96.1%。

核心结论

  • BA联合cCRT后BA相比安慰剂联合cCRT后度伐利尤单抗在不可切除III期非小细胞肺癌患者中未显示出疗效获益。

研究设计与样本

  • 多中心、双盲、对照2期研究(NCT03840902),评估BA联合cCRT后BA与安慰剂联合cCRT后度伐利尤单抗在不可切除III期非小细胞肺癌患者中的安全性和疗效。
  • 共153例患者随机分配至BA组(n=75)或度伐利尤单抗组(n=78)。
  • 主要终点为研究者根据实体瘤疗效评价标准1.1版评估的无进展生存期。
  • 根据独立数据监查委员会的建议,研究在总生存数据(次要终点)成熟前终止。

主要发现

  • BA组与度伐利尤单抗组中位无进展生存期分别为12.8个月与14.6个月(分层风险比=1.48,95%CI:0.69-3.17)。
  • BA组与度伐利尤单抗组客观缓解率分别为29.3%与32.1%,疾病控制率分别为66.7%与70.5%。
  • BA组与度伐利尤单抗组任何级别治疗中出现的不良事件发生率分别为94.6%与96.1%。
  • BA组出血事件多为1级(21.6%)或2级(9.5%)。

局限性

  • 研究在总生存数据(次要终点)成熟前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Preclinical evaluation of bintrafusp alfa (BA) combined with radiotherapy revealed greater antitumor effects than BA or radiotherapy alone. In a phase 1 study, BA exhibited encouraging clinical activity in patients with stage IIIB or IV NSCLC who had received previous treatment. METHODS: This multicenter, double-blind, controlled phase 2 study (NCT03840902) evaluated the safety and efficacy of BA with concurrent chemoradiotherapy (cCRT) followed by BA (BA group) versus placebo with cCRT followed by durvalumab (durvalumab group) in patients with unresectable stage III NSCLC. The primary end point was progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1 as assessed by the investigator. On the basis of the recommendation of an independent data monitoring committee, the study was discontinued before the maturity of overall survival data (secondary end point). RESULTS: A total of 153 patients were randomized to either BA (n = 75) or durvalumab groups (n = 78). The median progression-free survival was 12.8 months versus 14.6 months (stratified hazard ratio = 1.48 [95% confidence interval: 0.69-3.17]), in the BA and durvalumab groups, respectively. Trends for overall response rate (29.3% versus 32.1%) and disease control rate (66.7% versus 70.5%) were similar between the two groups. Any-grade treatment-emergent adverse events occurred in 94.6% versus 96.1% of patients in the BA versus durvalumab groups, respectively. Bleeding events in the BA group were mostly grade 1 (21.6%) or 2 (9.5%). CONCLUSIONS: BA with cCRT followed by BA exhibited no efficacy benefit over placebo with cCRT followed by durvalumab in patients with stage III unresectable NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Vokes EE, Mornex F, Sezer A, et al. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study. J Thorac Oncol. 2023. PMID: 37797733. doi:10.1016/j.jtho.2023.09.1452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。